Channel passion into potential
Our clinical trials help us investigate our product candidates’ novel capabilities.
To learn more about our current clinical trials, including eligibility, locations, and the process for potentially participating in a study, visit clinicaltrials.gov in the U.S.,
clinicaltrialsregister.eu in the EU, or https://jrct.niph.go.jp in Japan.
Our Commitment to Clinical Trial Transparency
At Insmed, we are deeply committed to ensuring that our clinical research is conducted responsibly and transparently, in full compliance with applicable laws and regulations, while protecting patient data. We are proud to have dedicated and trained staff to ensure timely registration of clinical trials and communication of our research results, and we work closely with external experts and thought leaders to ensure our work reflects the latest clinical and scientific advances.
Our current clinical trial transparency practices include:
As guardians of data about the patients who use our medicines, as well as their caregivers and the healthcare professionals who serve them, we are committed to handling personal data in accordance with global laws and regulations that govern data protection and privacy.
Clinical Trial Registration
Insmed registers company-sponsored Phase 1 to 4 clinical trials on public clinical registry sites as required by global laws and regulations.
To learn more about our current clinical trials, please visit the following websites:
Clinical Trial Results
Insmed discloses company-sponsored Phase 1 to 4 clinical trial results on public registries in compliance with global results disclosure laws and regulations.
To find clinical trial results for our completed trials, please visit the following websites:
Clinical Trial Lay Language Summary Results
In addition to posting results from our clinical trials, Insmed discloses lay language summary results on https://www.trialsummaries.com to help ensure that our results are understandable to patients and other general audiences.
Our clinical trials
The Phase 3 ASPEN study of patients with non-cystic fibrosis bronchiectasis (NCFBE) is currently underway.
NTM LUNG DISEASE CAUSED BY MAC
If you have nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC), you may be eligible for our clinical trial.
If you have pulmonary hypertension associated with interstitial lung disease (PH-ILD) or pulmonary arterial hypertension (PAH), you may be eligible for an Insmed study.
To learn about study sites near you, email medicalinformation@Insmed.com, call 1-844-446-7633 (within the United States), or visit https://insmedv2stag.wpengine.com/med-info/ for a list of phone numbers outside the United States.
If you have chronic rhinosinusitis without nasal polyps (CRSsNP), you may be eligible for the Phase 2 BiRCh study.